Cardiovascular Systems Inc. (CSI) featured two-year data from its ORBIT II study of the company’s Diamondback 360 coronary orbital atherectomy system (OAS) in a late-breaking presentation at the 2015 Society for Cardiovascular Angiography and Interventions (SCAI) conference. Diamondback 360 is a U.S. Food and Drug Administration (FDA)-approved atherectomy technology indicated for the treatment of severely calcified lesions.

CardiAQ Valve Technologies announced U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval for a feasibility study of its second generation transfemoral (TF) and transapical (TA) transcatheter mitral valve implantation systems. The study will enroll up to 20 patients (10 TF and 10 TA) and multidisciplinary physician teams at select U.S. sites will start enrollment once hospital approvals and agreements are in place.


The buzz term “big data” has made a rapid entry onto the healthcare scene in the past couple years with promises of improving healthcare, but there are still many who are trying to figure out how exactly it will accomplish this. Efforts were made to explain big data and its application to healthcare at the American College of Cardiology (ACC) and Healthcare Information and Management Systems Society (HIMSS) meetings earlier this year.

 

Spok Inc. announced the availability of message notifications on the Apple Watch wrist wearable device to enable clinicians to enhance care coordination. The Spok Mobile secure texting app is currently used by numerous hospitals to give users quick access to the organization’s directory, allowing staff to communicate securely through encrypted text, image and video messages. In addition, the app can receive alerts from patient care, nurse call and other monitoring systems to speed response to critical situations.

Subscribe Now